MoonLake Immunotherapeutics and Komodo Health are teaming up to maximize the impact of MoonLake’s nanobody-based therapy in hidradenitis suppurativa (HS) and active psoriatic arthritis (PsA).
MoonLake will utilize Komodo’s Healthcare Map and platform technologies to enable data-driven decision-making across its clinical operations, medical, marketing, and market access teams.
MoonLake is developing sonelokimab, a novel investigational Nanobody for the treatment of inflammatory disease. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation,
“We need an experienced technology partner that can help accelerate our disease insights for our clinical, medical, and commercial endeavors,” says Tino Anthamatten, VP, Marketing & Market Access & Pricing, MoonLake Immunotherapeutics, in a news release. “Komodo’s data-driven intelligence is expected to be a critical tool as we work toward commercialization and delivering transformative therapies to patients.”
Using Komodo’s software applications and Healthcare Map, MoonLake was able to show that between 2016 and 2023, two million unique patients were diagnosed and treated for HS, not including undiagnosed and untreated patients. The data also revealed that, on average, 240,000 net new patients are diagnosed and treated each year. This data helps substantiate the prevalence of HS as ~2%, as stated in the literature.
The real-world insights from Komodo helped validate a future HS market size projected to exceed $10B by 2035. Today there is a notably low penetration of current biologics (around 3%) and a high dropout rate from these interventions within the first year (median treatment duration of 11 months in a real-world setting). Furthermore, these insights shed light on the challenges of care and that individuals living with HS are being lost in their treatment journey. More than 50-60% of patients take long-term antibiotics, and many are also prescribed steroids and/or opioids. This real-world perspective substantiates MoonLake’s market size estimates and highlights the need for more effective therapies.
“We are thrilled to support MoonLake’s efforts to advance scientific innovation and gain a deeper understanding of patient journeys and unmet needs for people living with inflammatory diseases,” says Web Sun, President and Co-Founder, Komodo Health. “As MoonLake expects to commence phase 3 trials, we look forward to helping their teams utilize data and analytics to evaluate the market, develop their go-to-market and commercialization strategy, and, most important, help quickly bring its Nanobody therapy to market, once approved, for patients who need it most.”
